贝达喹啉耐药分子机制研究进展  

Research progress of resistance and molecular mechanisms of bedaquiline

作　　者：童恩煜 潘军航[2] 张明五[2] 朱业蕾 吴坤阳 柳正卫[2] 蒋健敏[1] Tong Enyu;Pan Junhang;Zhang Mingwu;Zhu Yelei;Wu Kunyang;Liu Zhengwei;Jiang Jianmin(School of Public Health,Hangzhou Normal University,Hangzhou 311110,China;Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou 310051,China)

机构地区：[1]杭州师范大学公共卫生学院,杭州311110 [2]浙江省疾病预防控制中心,杭州310051

出　　处：《中华结核和呼吸杂志》2023年第3期284-290,共7页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：国家自然科学基金(82173581);浙江省医药卫生科技计划(2020keyan512)。

摘　　要：耐药性结核病已逐渐成为全球性公共卫生问题并引起全世界广泛重视。贝达喹啉作为一种新型抗结核药物, 对耐药性结核病具有显著的治疗效果。然而, 自2014年德国报告了首例贝达喹啉耐药患者后, 其耐药情况逐渐增多。本文综述了贝达喹啉的抗菌特性、作用机制和耐药性分子机制, 并探讨如何避免贝达喹啉耐药性的发生、延缓贝达喹啉耐药性的进展。Drug-resistant tuberculosis has gradually become a global public health problem that is gaining attention acround the world.A new anti-tuberculosis drug,bedaquiline(BDQ),has showed significant therapeutic efficacy in drug-resistant TB.However,since the first case of BDQ resistance was reported in 2014,its resistance has gradually increased.In this article,we reviewed the antimicrobial properties of BDQ,resistance characteristics and molecular mechanisms of BDQ resistance,and we also discussed the strategies to avoid the occurrence of BDQ resistance.

关 键 词：耐药分子机制 耐药性结核病 

分 类 号：R978.3[医药卫生—药品]